CSV November 24, 2022 through November 24, 2024 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ALMOTRIPTAN	ADDITIONAL R	*Second*	8708	17-Nov-2017	1-Dec-2017	*USP42–NF37*	*Second*	Line 4 of USP

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TABLETS	EQUIREMENTS/*USP Reference Standards <11>*	*Supplement to USP40–NF35*					*Supplement to USP41–NF36*	Almotriptan Related Compound B RS: Change $C_{15}H_{22}N_3O_2S$ to: $C_{15}H_{21}N_3O_2S$ AND Line 2 of USP Almotriptan Related Compound D RS: Change 1-[({3-[2-(Dimethylamino)ethyl]indol-5-yl}methyl)sulfonyl]pyrrolidine *N*-oxide. $C_{17}H_{25}N_3O_3S$ 351.46 to: 1-[({3-[2-(Dimethylamino)ethyl]indol-5-yl}methyl)sulfonyl]pyrrolidine *N*-oxide hydrochloride. $C_{17}H_{25}N_3O_3S \cdot HCl$ 387.92
HAZARDOUS DRUGS—HAND	7. PERSONAL PROTECTIVE	*First Supplement to*	Online	17-Nov-2017	1-Dec-2017	*USP42–NF37*	*Second Supplement to*	Line 2 of paragraph 2:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
LING IN HEALTHCARE SETTINGS	EQUIPMENT	*USP40–NF35*					*USP41–NF36*	Change antineoplastic HDs. to: injectable antineoplastic HDs.
CHLOROQUINE PHOSPHATE	IMPURITIES/*Organic Impurities*	*USP40–NF35*	3377	17-Nov-2017	1-Dec-2017	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 3 of *Analysis*: Change Calculate the percentage of each specified impurity to: Calculate the percentage of each specified impurity, other than chloroquine related compound G, AND In *Analysis*/second equation/variable definition list: Change r_U=peak response of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								chloroquine *N*-oxide or any other impurity from the *Sample solution* r_U=peak response of chloroquine related compound G or any other impurity from the *Sample solution*
GLUTARAL CONCENTRATE	ASSAY/ *Procedure*	*USP40–NF35*	4414	17-Nov-2017	1-Dec-2017	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 7 of *Analysis*: Change Add a weighed quantity of Concentrate containing 1.2 g of glutaral by means of a suitable weighing pipet. to: Add 1.2 g of Glutaral Concentrate.
MYCOPHENOLIC ACID DELAYED	PUR	*USP40–NF35*	5257	17-Nov-2017	1-Dec-2017	*USP42–NF37*	*Second Supplement to*	Change *Mobile phase*,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ED-RELEASE TABLETS	ITIES/*Organic Impurities*						*USP41–NF36*	*Standard solution*, *Sample solution*, and *Chromatographic system*: to: *Mobile phase*, *Diluent*, *Standard solution*, *Sample solution*, and *Chromatographic system*:
VISUAL INSPECTION OF INJECTIONS	4. INSPECTION LI FE-CYCLE/*4.2 Prevention of Particulates*	*First Supplement to USP40–NF35*	8099	17-Nov-2017	1-Dec-2017	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 5 of paragraph 1 of *Robust Design During Development*: Change lamellae (*46*,*47*) to: lamellae as discussed in *Evaluation of the Inner Surface Durability of Glass Containers*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								<1660> and by the FDA (*45*) AND Line 2 of paragraph 4 of *Robust Design During Development*: Change (ICH)-relevant trials. to: (ICH)-relevant trials (*46*).
SODIUM LAURYL SULFATE	IDENTIFICATION	*Second Supplement to USP40–NF35*	8946	17-Nov-2017	1-Dec-2017	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 1 of *A.*: Change Infrared Absorption <197K> or <197A> to: ?A. Infrared Absorption <197K> or <197A>?
DEXCHLORPHENIRAMINE MALEATE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP40–NF35*	3685	17-Nov-2017	1-Dec-2017	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 2 of USP Chlorpheniramine Related Compound C RS: Change 3-(4-Chlorophe

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								nyl-*N*-methyl-3-(pyridin-2-yl)propan-1-amine. $C_{15}H_{17}ClN_2$ 260.76 to: 3-(4-Chlorophenyl)-*N*-methyl-3-(pyridin-2-yl)propan-1-amine maleate. $C_{15}H_{17}ClN_2 \cdot C_4H_4O_4$ 376.83
IRINOTECAN HYDROCHLORIDE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP40–NF35*	4676	17-Nov-2017	1-Dec-2017	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 2 of USP Irinotecan Related Compound C RS: Change (*S*)-9-[(1,4?-Bipiperidine)-1?-carbonyloxy]-4-methyl-11-ethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1*H*-pyrano[3?,4?:6,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								b]quinoline hydrochloride. to: 11-Ethyl-4-hydroxy-4-methyl-3,14-dioxo-3,4,12,
								H-pyrano[3?,4?:6,
								b]quinolin-9-yl (1,4?-bipiperidine)-1?-carboxylate hydrochloride.
CALCIUM STEARATE	IDENTIFICATION	*USP40–NF35*	7557	17-Nov-2017	1-Dec-2017	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 3 of *B.*: Change obtained in the *Assay*. to: obtained in the *Assay* for *Content of Stearic Acid and Palmitic Acid*.
DIVALPROEX SODIUM EXTE	ASSAY/ *Procedure*	*Second Supplement to*	8752	17-Nov-2017	1-Dec-2017	*USP42–NF37*	*Second Supplement to*	Line 2of *Mobile phase*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
NDED-RELEASE TABLETS		*USP40–NF35*					*USP41–NF36*	Adjust with phosphoric acid to a pH of 5.0. to: Adjust with diluted sodium hydroxide or phosphoric acid to a pH of 5.0.
IDENTIFICATION TESTS—GENERAL	CHEMICAL IDENTIFICATION TESTS/ *Thiosulfate*	*Second Supplement to USP40–NF35*	Online	17-Nov-2017	1-Dec-2017	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 1 of *A*.: Change yellow; with the addition of sulfur dioxide, filter paper moistened with mercurous nitrate TS blackens. to: yellow, and evolve sulfur dioxide, which blackens filter paper moistened with mercurous nitrate TS.
CHLORPHENIRAMINE MALEATE	ADDITIONAL REQUIREMENTS/*USP*	*USP40–NF35*	3385	17-Nov-2017	1-Dec-2017	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 2 of USP Chlorpheniramine Related

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Reference Standards <11>							Compound C RS: Change 3-(4-Chlorophenyl-*N*-methyl-3-(pyridin-2-yl)propan-1-amine. $C_{15}H_{17}ClN_2$ 260.76 to: 3-(4-Chlorophenyl)-*N*-methyl-3-(pyridin-2-yl)propan-1-amine maleate. $C_{15}H_{17}ClN_2 \cdot C_4H_4O_4$ 376.83
HYDROXYZINE HYDROCHLORIDE	ASSAY/ *Procedure*	*USP40–NF35*	4539	17-Nov-2017	1-Dec-2017	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 2 of *Solution B*: Change (0.5: 99.5) to: (0.05: 99.95)
PILOCARPINE HYDROCHLORIDE OPHTHALMIC SOLUTION	ASSAY/ *Procedure*	*USP40–NF35*	5706	17-Nov-2017	1-Dec-2017	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 2 of *Standard solution*: Change water to: methanol
HYDROXYZINE	ASSAY/	*First*	8299	17-Nov-2017	1-Dec-2017	*USP42–NF37*	*Second*	Line 2 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
HYDROCHLORIDE ORAL SOLUTION	*Procedure*	*Supplement to USP40–NF35*					*Supplement to USP41–NF36*	*Solution B*: Change (0.5: 99.5) to: (0.05: 99.95)
HAZARDOUS DRUGS—HANDLING IN HEALTHCARE SETTINGS	5. FACILITIES AND ENGINEERING CONTROLS/*5.4 Containment Supplemental Engineering Controls*	*First Supplement to USP40–NF35*	Online	17-Nov-2017	1-Dec-2017	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 5 of paragraph 1: Change containment reduction. to: contamination reduction.
DONEPEZIL HYDROCHLORIDE	IMPURITIES/*Organic Impurities, Procedure 2*	*USP40–NF35*	3859	17-Nov-2017	1-Dec-2017	*USP42–NF37*	*Second Supplement to USP41–NF36*	Footnote b of *Table 3*: Change (*E*)-4-[(5,6-Dimethoxy-1-oxo-1*H*-inden-2-yl)methyl]pyridine 1-oxide. to: (*E*)-4-[(5,6-Dimethoxy-1-oxo-1,3-dihydro-2*H*-inden-2-ylidene)methyl]pyridine 1-oxide.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
MYCOPHENOLIC ACID DELAYED-RELEASE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*	*USP40–NF35*	5257	17-Nov-2017	1-Dec-2017	*USP42–NF37*	*Second Supplement to USP41–NF36*	In *Acid stage/ Analysis*/variable definition list: Change *V* = volume of *Medium*, 750 mL to: *V* = volume of *Acid stage medium*, 750 mL AND In *Buffer stage/ Analysis*/variable definition list: Change *V* = volume of *Medium*, 1000 mL to: *V* = volume of *Buffer stage medium*, 1000 mL
VISUAL INSPECTION	2. BACKGROUND/*2.2 Patient*	*First Supplement to*	8099	17-Nov-2017	1-Dec-2017	*USP42–NF37*	*Second Supplement to*	Line 6 of paragraph 3:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
OF INJECTIONS	*Risk*	*USP40–NF35*					*USP41–NF36*	Change 109 particles/kg to: 10^9 particles/kg
FLUVOXAMINE MALEATE	ASSAY/ *Procedure*	*Second Supplement to USP40–NF35*	8797	17-Nov-2017	1-Dec-2017	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 2of *Solution A*: Change 1 g/L to: 1.1 g/L
ALMOTRIPTAN MALATE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*Interim Revision Announcement (Official May 01, 2017)*	Online	17-Nov-2017	1-Dec-2017	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 2 of USP Almotriptan Related Compound D RS: Change 1-[({3-[2-(Dimethylamino)ethyl]indol-5-yl}methyl)sulfonyl]pyrrolidine *N*-oxide. $C_{17}H_{25}N_3O_3S$ 351.46 to: 1-[({3-[2-(Dimethylamino)ethyl]indol-5-yl}methyl)sulfonyl]pyrrolidine *N*-oxide hydrochloride. $C_{17}H_{25}N_3O_3S \cdot HCl$ 387.92

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
REAGENTS	REAGENT SPE *Bromelain/Activity Determination*	*USP40–NF35*	2339	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1 of *Buffer solution*: Change Add 150 mg of sodium chloride to: Add 150 g of sodium chloride
FENOLDOPAM MESYLATE	*USP Reference standards <11>*	*USP40–NF35*	4159	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 2 of USP Fenoldopam Related Compound A RS: Change 1-Methyl-3-benzazepine-7,8-diol, 6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-, methanesulfonate (salt). $C_{17}H_{18}ClNO_3 \cdot CH_4SO_3$ 415.89 to: 6-Chloro-1-(4-hydroxyphenyl)-3-methyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine-7,8-dio

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								l hydrochloride (*N* -Methyl-6-chloro -2,3,4,5-tetrahy dro-1-(4-hydrox yphe nyl)-1*H* -3-benzazepine- 7,8-diol hydrochloride). $C_{17}H_{19}ClNO_3$ · HCl 356.24
MEBENDAZOLE	IM PUR ITIES/*Organic Impurities*/*Table 2*	*USP40–NF35*	4968	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Change footnotes [d]Ethyl 5-benzoyl -1-methylbenzi midazol-2-ylcar bamate. [e]Methyl 5-(4-tol uoyl)-1-methylb enzimidazol-2-yl carbamate. to: [d]Ethyl (5- benzo yl-1*H* -benzimidazol-2 -yl)carbamate. [e]Methyl 5-

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								(4-toluoyl)-1*H*-benzimidazol-2-ylcarbamate.
MYCOPHENOLATE SODIUM	IMPURITIES/*Organic Impurities*	*USP40–NF35*	5256	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Footnote a of *Table 2*: Change (*RS*)-7-Hydroxy-5-methoxy-4-methyl-6-[2-(5-methyl-2-oxo-tetrahydrofuran-5-yl)ethyl]-3*H*-isobenzofuranyl-1-one. to: (*RS*)-7-Hydroxy-5-methoxy-4-methyl-6-[2-(5-methyl-2-oxo-tetrahydrofuran-5-yl)ethyl]-3*H*-isobenzofuran-1-one.
CANDESARTAN CILEXETIL TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference*	*Second Supplement to USP40–NF35*	8730	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 2 of USP Candesartan Cilexetil Related Compound D

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Standards <11>							RS: Change 1-{[(Cyclohexyloxycarbonyloxy)carbonyl]oxy}ethyl *H* -tetrazol-5-yl)biphenyl-4-yl]methyl}-2-oxo-2,3-dihydro-1*H* -benzimidazole-4-carboxylate. to: 1-{[(Cyclohexyloxy)carbonyl]oxy}ethyl *H* -tetrazol-5-yl)-[1 ,1'-biphenyl]-4-yl}methyl)-2-oxo-2, 3-di hydro-1*H* -benzimidazole-4-carboxylate.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ENALAPRIL MALEATE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>/Table 1*	*USP40–NF35*	3971	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Row 3 of Column 3: Change 100 to: 200
ISOSORBIDE DINITRATE EXTENDED-RELEASE TABLETS	*Assay*	*USP40–NF35*	4710	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Change *Buffer solution*, *Mobile phase*, *Internal standard solution*, *Standard preparation*, and *Chromatographic system*—Prepare as directed in the *Assay* under *Diluted Isosorbide Dinitrate*. to: *Buffer solution*—Dissolve 15.4 g of ammonium acetate in water, add 11.5 mL of glacial

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								acetic acid, dilute with water to 1000 mL, and mix to obtain a solution having a pH of about 4.7. *Mobile phase*—Mix 350 mL of water, 100 mL of *Buffer solution*, and 550 mL of methanol. Cool to room temperature, dilute with water to 1000 mL, mix, degas, and filter. Make adjustments if necessary (see *System Suitability* under *Chromatography <621>*). *Internal standard solution*—Transfer a quantity of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								diluted nitroglycerin to a suitable volumetric flask, add about 60% of the flask volume of methanol, sonicate for 5 minutes, and shake for 30 minutes. Dilute with methanol to volume to obtain a solution having a concentration of about 3 mg of nitroglycerin per mL, and mix. Allow any undissolved material to settle, filter, and store the filtrate in an airtight container. *Standard prep aration* —Transfer about

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								125 mg of recently mixed USP Diluted Isosorbide Dinitrate RS, accurately weighed, to a 50-mL volumetric flask, add about 30 mL of *Mobile phase*, shake for 30 minutes, dilute with *Mobile phase* to volume, and mix. Pipet 10 mL of the resulting solution into a 25-mL volumetric flask, and add 4.0 mL of *Internal standard solution* and 4 mL of dilute *Buffer solution* (1 in 10). Cool to room temperature,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								dilute with *Mobile phase* to volume, and mix to obtain a solution having a known concentration of about 0.25 mg of isosorbide dinitrate per mL, based on the quantity of USP Diluted Isosorbide Dinitrate RS weighed and the labeled content of isosorbide dinitrate. Pass a portion of this solution through a 0.45-µm filter. AND Change *Proce dure*—Proceed as directed for *Procedure* in the *Assay* under *Diluted*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Isosorbide Dinitrate. to: *Chromatographic system* (see *Chromatography <621>*)—The liquid chromatograph is equipped with a 220-nm detector and a 4-mm × 25-cm column that contains packing L1. The flow rate is about 1 mL per minute. Chromatograph the *Standard preparation*, and record the peak responses as directed for *Procedure*: the resolution, *R*, between isosorbide dinitrate and nitroglycerin is

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								not less than 2.0; and the relative standard deviation for replicate injections determined from the peak response ratios is not more than 2%. [NOTE—The relative retention times are about 0.75 for isosorbide dinitrate and 1.0 for nitroglycerin. The relative retention times for isosorbide mononitrates, if present, are about 0.38.] *Proce dure* —Separately inject equal volumes (about 20 µL) of the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Standard preparation and the *Assay preparation* into the chromatograph, record the chromatograms, and measure the responses for the major peaks.
MYCOPHENOLATE MOFETIL FOR ORAL SUSPENSION	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP40–NF35*	5251	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 2 of USP Mycophenolate Mofetil Related Compound B RS: Change (*RS*)-7-Hydroxy-5-methoxy-4-methyl-6-[2-(5-methyl-2-oxo-tetrahydrofuran-5-yl)ethyl]-3*H*-isobenzofuranyl-1-one. to: (*RS*)-7-Hydroxy-5-methoxy-4-methyl-6-[2-(5-methy

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								l-2-oxo-tetrahydrofuran-5-yl)ethyl]-3*H*-isobenzofuran-1-one.
POWDERED ASHWAGANDHA ROOT EXTRACT	COMPOSITION */Content of Withanolides*	*USP40–NF35*	6804	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Add *Solution B*: Acetonitrile, filtered and degassed
EFAVIRENZ	SPECIFIC TESTS/ *Enantiomeric Purity*	*Second Supplement to USP40–NF35*	Online	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1 of *Mobile phase*: Change Hexane and ethanol (97:3) to: Hexane and absolute alcohol (97:3)
REAGENTS, INDICATORS AND SOLUTIONS	SOLUTIONS/*Volumetric Solutions*/*1 N Sulfuric Acid VS*	*USP40–NF35*	2434	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 3 of *Standardization*: Change dried at 150° to: dried at 105°
GADOTERIDOL	*Chromatographic purity*/*Test 2 (Nongadolinium-Containing Impurities)*	*USP40–NF35*	4360	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1 of *pH 5.0 Buffer*: Change *50 mM Ammonium* to: *50 mM Ammonium*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								phosphate buffer AND Line 1 of *pH 7.0 Buffer*: Change *50 mM Ammonium* to: *50 mM Ammonium phosphate buffer*
MEMANTINE HYDROCHLORIDE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>/Analysis*	*USP40–NF35*	5000	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	In the variable definition list: Change C_S = concentration of USP Memantine Hydrochloride RS in the *Standard solution* (µg/mL) to: C_S = concentration of USP Memantine Hydrochloride RS in the *Standard stock*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution (mg/mL)
PEMETREXED DISODIUM	IMPURITIES/*Organic Impurities*/*Table 2*	*USP40–NF35*	5588	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Footnote b: Change {4-[2-(2-Amino-1-methyl-4-oxo-4,7-dihydro-1*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)ethyl]benzoyl}-4-L-glutamyl-L-glutamic acid. to: {4?[2?(2?Amino?4?oxo?4,7?dihydro?1*H*?pyrrolo[2,3?*d*]pyrimidin?5?yl)ethyl]benzoyl}?4?L?glutamyl?L?glutamic acid.
FLUVOXAMINE MALEATE	CHEMICAL INFORMATION	*Second Supplement to USP40–NF35*	8797	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 4:Change 5-Methoxy-4’-(trifluoromethyl)valerophenone

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								(*E*)-*O*-(2-aminoethyl) oxime, maleate (1:1) to: (*E*)-5-Methoxy-4'-(trifluoromethyl) valerophenone *O*-(2-aminoethyl) oxime, maleate (1:1)
ENOXAPARIN SODIUM INJECTION	SPECIFIC TESTS/*Anti-Factor IIa Activity*	*USP40–NF35*	3982	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Delete *Standard solutions*: Dilute USP Enoxaparin Sodium Solution for Bioassays RS with *pH 7.4 buffer* to obtain four dilutions having concentrations in the range between 0.015 and 0.075 IU of Anti-Factor IIa activity/mL.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ISOSORBIDE DINITRATE EXTENDED-RELEASE TABLETS	*Dissolution <711>/Test 2*	*USP40–NF35*	4710	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1: Change *Buffer solution* and *Mobile phase*—Prepare as directed in the *Assay* under *Diluted Isosorbide Dinitrate*. to: *Buffer solution* and *Mobile phase*—Prepare as directed in the *Assay*. AND Line 1 of *Chromatographic system*: Change (see *Chromatography <621>*)—Proceed as directed in the *Assay* under *Diluted Isosorbide Dinitrate*. to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								(see *Chromatography* *<621>*)—Proceed as directed in the *Assay*.
MYCOPHENOLATE SODIUM	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP40–NF35*	5256	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 2 of USP Mycophenolate Mofetil Related Compound B RS: Change (*RS*)-7-Hydroxy-5-methoxy-4-methyl-6-[2-(5-methyl-2-oxo-tetrahydrofuran-5-yl)ethyl]-3*H* -isobenzofuranyl-1-one. to: (*RS*)-7-Hydroxy-5-methoxy-4-methyl-6-[2-(5-methyl-2-oxo-tetrahydrofuran-5-yl)ethyl]-3*H* -isobenzofuran-1-one.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
MONOBASIC POTASSIUM PHOSPHATE	IMPURITIES/*Arsenic, Method I <211>*	*USP40–NF35*	7847	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1: Change 3 µg/g to: NMT 3 µg/g
POTASSIUM CITRATE EXTENDED-RELEASE TABLETS	ASSAY/*Procedure*	*Revision Bulletin (Official April 01, 2017)*	Online	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1 of *Chromatographic system*/*Column*: Change 10-µm to: 5-µm AND In the variable definition list in *Analysis*: Change r_U = citrate peak area from the *Sample solution* r_S = citrate peak area from the *Standard solution* to: r_U = citric acid peak area from the *Sample solution* r_S = citric acid peak area from

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								the *Standard solution* AND Change M_{r2} = molecular weight of citrate ($C_6H_5O_7$), 189.10 to: M_{r2} = molecular weight of citric acid ($C_6H_8O_7$), 192.13
CALCIPOTRIENE OINTMENT	IMPURITIES/*Organic Impurities*	*USP40–NF35*	3114	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Footnote a of *Table 1*: Change (5*Z*,7*Z*,22*E*,24*R*)-24-Cyclopropyl-9,10-secochola-5,7,10(19),22-tetraene-1?,3?,24-triol. to: (5*Z*,7*Z*,22*E*,24*S*)-24-Cyclopropyl-9,10-secochola-5,7,10(19),22-tetraene-1?,3?,24-triol.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ISOSORBIDE DINITRATE EXTENDED-RELEASE CAPSULES	*Assay*	*USP40–NF35*	4708	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Change *Buffer solution*, *Mobile phase*, *Internal standard solution*, *Standard preparation*, and *Chromatographic system*—Prepare as directed in the *Assay* under *Diluted Isosorbide Dinitrate*. to: *Buffer solution*—Dissolve 15.4 g of ammonium acetate in water, add 11.5 mL of glacial acetic acid, dilute with water to 1000 mL, and mix to obtain a solution having a pH of about

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								4.7. *Mobile phase*—Mix 350 mL of water, 100 mL of *Buffer solution*, and 550 mL of methanol. Cool to room temperature,dilute with water to 1000 mL, mix, degas,and filter. Make adjustments if necessary (see *System Suitability* under *Chromatography <621>*). *Internal standard solution*—Transfer a quantity of diluted nitroglycerin to a suitable volumetric flask, add about 60%

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								of the flask volume of methanol, sonicate for 5 minutes, and shake for 30 minutes. Dilute with methanol to volume to obtain a solution having a concentration of about 3 mg of nitroglycerin per mL, and mix. Allow any undissolved material to settle, filter, and store the filtrate in an airtight container. *Standard prep aration* —Transfer about 125 mg of recently mixed USP Diluted Isosorbide Dinitrate RS,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								accurately weighed, to a 50-mL volumetric flask, add about 30 mL of *Mobile phase*, shake for 30 minutes, dilute with *Mobile phase* to volume, and mix. Pipet 10 mL of the resulting solution into a 25-mL volumetric flask, and add 4.0 mL of *Internal standard solution* and 4 mL of dilute *Buffer solution* (1 in 10). Cool to room temperature, dilute with *Mobile phase* to volume, and mix to obtain a solution having

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								a known concentration of about 0.25 mg of isosorbide dinitrate per mL, based on the quantity of USP Diluted Isosorbide Dinitrate RS weighed and the labeled content of isosorbide dinitrate. Pass a portion of this solution through a 0.45-µm filter. AND Change *Proce dure*—Proceed as directed for *Procedure* in the *Assay* under *Diluted Isosorbide Dinitrate*. to: *Chromatographi c system* (see

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Chromatography <*621*>)—The liquid chromatograph is equipped with a 220-nm detector and a 4-mm × 25-cm column that contains packing L1. The flow rate is about 1 mL per minute. Chromatograph the *Standard preparation*, and record the peak responses as directed for *Procedure*: the resolution, *R*, between isosorbide dinitrate and nitroglycerin is not less than 2.0; and the relative standard deviation for

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								replicate injections determined from the peak response ratios is not more than 2%. [NOTE—The relative retention times are about 0.75 for isosorbide dinitrate and 1.0 for nitroglycerin. The relative retention times for isosorbide mononitrates, if present, are about 0.38.] *Procedure*—Separately inject equal volumes (about 20 µL) of the *Standard preparation* and the *Assay preparation* into the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								chromatograph, record the chromatograms, and measure the responses for the major peaks.
MYCOPHENOLATE MOFETIL FOR INJECTION	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP40–NF35*	5250	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 2 of USP Mycophenolate Mofetil Related Compound B RS: Change (*RS*)-7-Hydroxy-5-methoxy-4-methyl-6-[2-(5-methyl-2-oxo-tetrahydrofuran-5-yl)ethyl]-3*H*-isobenzofuranyl-1-one. to: (*RS*)-7-Hydroxy-5-methoxy-4-methyl-6-[2-(5-methyl-2-oxo-tetrahydrofuran-5-yl)ethyl]-3*H*-isobenzofuran-1-one.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
PEMETREXED FOR INJECTION	ASSAY/*Procedure/Analysis*	*USP40–NF35*	5590	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	In the variable definition list: Change M_{r2} = molecular weight of pemetrexed disodium, 597.49 to: M_{r2} = molecular weight of pemetrexed disodium (anhydrous), 473.37
FLUVOXAMINE MALEATE	IMPURITIES/*Organic Impurities/Table 1*	*Second Supplement to USP40–NF35*	8797	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Footnote b:Change 5-Methoxy-1-[4-(trifluoromethyl)phenyl]-1-pentanone (*E*)-*O*-[2-[(2-succinyl)amino]ethyl]oxime. to: (*E*)-5-Methoxy-1-[4-(trifluoromethyl)phenyl]-1-pentanone *O*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-[2-[(2-succinyl) amino]ethyl]oxime. AND Footnotes c– g: Delete the space before oxime
ERYTHROMYCIN OPHTHALMIC OINTMENT	ASSAY/ *Procedure/Analysis*	*First Supplement to USP40–NF35*	8276	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 9 of the third variable definition list: Change *P* = potency of erythromycin C in USP Erythromycin B RS (mg/mg) to: *P* = potency of erythromycin C in USP Erythromycin C RS (mg/mg)
VITAMIN D ASSAY	ASSAY/ *Chromatographic Methods/Procedure 8*	*USP40–NF35*	462	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	*Clean-up chromatographic system*: Add *Flow rate*: 1.1 mL/min AND *Analytical chromatographic*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								system: Add *Flow rate*: 1.0 mL/min
ONDANSETRON TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP40–NF35*	5445	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 2 of USP Ondansetron Related Compound A RS: Change 3[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4*H*-carbazol-4-one. to: 3-[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4*H*-carbazol-4-one hydrochloride.

Pagination

- First page « First
- Previous page ‹ Previous
- …
- Page 9
- Page 10

- Page 11
- Page 12
- Page 13
- Page 14
- Page 15
- Page 16
- Page 17
- …
- Next page Next ›
- Last page Last »